On average, male rheumatologists earn 16.2%—or $38,493—more than female rheumatologists. Although the data seem jarring, a closer look at it is needed to truly understand the pay gap…

On average, male rheumatologists earn 16.2%—or $38,493—more than female rheumatologists. Although the data seem jarring, a closer look at it is needed to truly understand the pay gap…
Paul M. Adam, MSW, & Afton L. Hassett, PsyD |
Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. The ARHP Online Education Portfolio continues to evolve and grow. The Advanced Rheumatology Course (ARC) and the Fundamentals of Rheumatology Course (FRC)…
Gregory Taylor, MSW, RCSW |
Often, young adults (18–23 years old) with rheumatic illness demonstrate poor adherence to treatment regimens, lack advocacy skills and have inadequate knowledge about diagnosis and treatment.1 Patients presenting at a transition clinic are typically comfortable with having their parents continue to be centrally involved with their care, but this is a time in life when…
Alexandra Perel-Winkler, MD, & Christopher A. Mecoli, MD |
Introduction Interest in rheumatology continues to grow, with more than 240 new adult and pediatric fellows to begin their training in the coming academic year. Given the broad and diverse career opportunities, it is an ACR goal to help guide trainees in their career decisions and professional development. Rheumatology fellowship often marks the transition from…
Lisa G. Rider, MD, & Frederick W. Miller, MD, PhD |
Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…
“It is not necessary to change. Survival is not mandatory.” —W. Edwards Deming For practices to survive, change is a requirement—not an option—in the rapidly evolving practice of rheumatology care. Pharmaceutical therapies are advancing quickly, opening the door for game-changing therapies in the treatment of chronic autoimmune disorders. With these advances comes a need for…
WASHINGTON, D.C.—Addressing a gathering of healthcare providers at the 2016 ACR/ARHP Annual Meeting concurrent session titled, Pediatric Rheumatology for the Adult Rheumatologist, part of the ACR Review Course, expert Sangeeta Sule, MD, PhD, associate professor of pediatrics specializing in rheumatology at Johns Hopkins Hospital in Baltimore, displayed a color-coded map of the U.S. on which…
GCA Relapse Possible When Discontinuing Tocilizumab In a Phase 2 randomized, controlled trial, tocilizumab, an anti-IL-6 biologic agent, was shown to induce and maintain remission for up to 52 weeks in patients with giant cell arteritis (GCA).1 During this trial, patients with GCA were randomized in a 2:1 ratio to receive 8 mg/kg bodyweight tocilizumab…
For they’re some very good fellows … no, seriously. They are this year’s recipients of the ACR Distinguished Fellows Awards. The Rheumatologist spoke with them about their burgeoning contributions to Advancing Rheumatology! ACR Distinguished Fellow Awards Eric Allenspach, MD, PhD Acting Assistant Professor, Seattle Children’s Hospital, Seattle Background: Dr. Allenspach seeks to understand the genetic basis…
Sharad Lakhanpal, MBBS, MD |
Ten years have elapsed since the ACR conducted its last workforce study, and we know that much has changed. The comprehensive patient-centered, integrative approach to the 2015 ACR/ARHP Workforce Study of Rheumatology Specialists in the United States (now publicly available) describes the character and composition of the current clinical workforce, recognizes demographic and employment trends,…